Organization
Southern Medical University
1 clinical trial
30 abstracts
Abstract
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Medical Oncology, Yale School of Medicine, Yale Cancer Center, Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.Org: Guangdong Lung Cancer Institute, Southern Medical University, First Affiliated Hospital of Zhengzhou University, Shanxi Cancer Hospital, The First Affiliated Hospital/School of Clinical Medicine Guangdong Pharmaceutical University,
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
An MRI-based multi-parameter clinical decision support system (NeoMDSS) for early prediction of pathological complete response after the first cycle of neoadjuvant therapy in breast cancer: A multi-center prospective observational cohort study.Org: Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Academy of Medical Sciences, Southern Medical University, Department of Vascular Surgery,
Abstract
Effect of combination of genomic variation–based machine learning and clinical pathology on accurate diagnosis of tumors: Lung adenocarcinoma and lung squamous cell carcinoma.Org: Nanhai People's Hospital, the Second School of Clinical Medicine, Southern Medical University, Foshan, China, The Second Hospital of Tianjin Medical University,
Abstract
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,
Abstract
FGF19-FGFR4 axis as the inaugural target for determining the efficacy of advanced esophageal cancer treatment.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Nanfang Hospital, Southern Medical University,
Abstract
BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in-human phase I study in patients with advanced solid malignancies.Org: Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Biocity Biopharmaceutics, Shanghai, China, Gracell Biotechnologies, Ltd.,
Clinical trial
Clinical Study for Evaluating the Effectiveness of Haloperidol and Temozolomide Synergism on Adult Recurrence GlioblastomaStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Abstract
Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.Org: Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,
Abstract
Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.Org: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Chinese Academy of Medical Science & Peking Union Medical Co,
Abstract
Prospective dynamic sampling and molecular residual disease monitoring to predict clinical outcomes for patients with unresectable, locally advanced non-small cell lung cancer undergoing radical radiotherapy.Org: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Southern Medical University, Geneplus-Beijing, Beijing, China, Geneplus-Beijing Institute,
Abstract
Pretreatment radiomic biomarker for immunotherapy responder prediction in IB-IV stage NSCLC: A multi-center retrospective study.Org: Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Southern Medical University, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangdong Provincial People's Hospital, Guangzhou JOYO Pharma,
Abstract
Magnetic resonance imaging tumor regression shrinkage patterns during neoadjuvant chemotherapy versus neoadjuvant immunochemotherapy in triple-negative breast cancer (NeoMDSS-TN-SP): A nonrandomized, prospective cohort study.Org: Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou JOYO Pharma,
Abstract
Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).Org: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Affiliated Dongguan Hospital,
Abstract
Longitudinal MRI-based radiomic model to complement sentinel lymph node biopsy assessment after neoadjuvant chemotherapy in initially clinically node-positive breast cancer: A multicentre, diagnostic study.Org: Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Southern Medical University, The First People’s Hospital of Foshan,
Abstract
Genomic landscape of CDK6 amplification and its potential prognostic value in adult-type diffuse gliomas.Org: Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Nanfang Hospital, Southern Medical University, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
Landscape of FGFR2/3 alterations in hepatobiliary malignancies.Org: Nanfang Hospital, Southern Medical University, Guangzhou, China, AcornMed Biotechnology Co., Ltd., Beijing, China, Beijing, China,
Abstract
Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.Org: Memorial Sloan-Kettering Cancer Center, Knapp Center for Biomedical Discovery, The University of Chicago Medicine Center for Advanced Care at Orland Park, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Thoraxklinik,
Abstract
Droplet digital PCR as an alternative method for detecting MET amplification in patients with non-small cell lung cancer.Org: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Southern Medical University Guangzhou, Southern Medical University,
Abstract
A retrospective study on the efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in gastrointestinal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma,
Abstract
Preliminary dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).Org: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, Genesis Care North Shore, North Shore Health Hub, St Leonards, NSW, Australia,
Abstract
Influence of CD47 on CD8+ T-cell and tumor prognosis based on pan-cancer analysis.Org: Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou University of Chinese Medicine, Southern Medical University,
Abstract
Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.Org: Guangdong Provincial People's Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China,
Abstract
Radiation-sensitive genetic prognostic model to identify individuals at risk for radiation resistance in head and neck squamous cell carcinoma.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Cancer Hospital of Nanchang University, Jiangxi Key Laboratory of Translational Cancer Research, Jiangxi Cancer Hospital of Nanchang University, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Characteristics and trends of globally registered malignant pleural mesothelioma clinical trials in the past 27 years.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China, Guangdong Provincial People's Hospital,
Abstract
A 9-gene signature in circulating tumor DNA based on molecular residual disease detection to predict recurrence of resectable non–small-cell lung cancer.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Berry Oncology Corporation,
Abstract
APTAMER-MODIFIED TETRAHEDRAL FRAMEWORK NUCLEIC ACID SYNTHESIZED WITH TGF-β3 TO PROMOTE CARTILAGE REPAIR IN OSTEOARTHRITIS BY ENHANCING CHONDROGENIC DIFFERENTIATION OF MESENCHYMAL STEM CELLSOrg: Zhujiang Hospital, Southern Medical University, Clinical Research Centre, Orthopedic Centre, Guangzhou, China,
Abstract
ASSOCIATIONS BETWEEN METABOLIC STATUS AND ALL-CAUSE MORTALITY AMONG INDIVIDUALS WITH OSTEOARTHRITIS: A PROSPECTIVE COHORT STUDY FROM THE UK BIOBANK AND NHANES DATASETSOrg: Zhujiang Hospital, Southern Medical University, Clinical Research Centre, General Hospital of Southern Theater Command of PLA, Department of Orthopedics, Clinical Research Centre, Guangzhou, China, The Hong Kong Polytechnic University,
Abstract
ASSOCIATION OF HEALTHY LIFESTYLES WITH ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY AMONG INDIVIDUALS WITH OSTEOARTHRITIS: A PROSPECTIVE COHORT STUDY OF THE UK BIOBANKOrg: Zhujiang Hospital, Southern Medical University, Clinical Research Centre, Guangzhou JOYO Pharma, China National Biotec Group,